December 20, 2022

2 Min Read
ITB21_Newsletter_1540x800_0_0.jpg

No chance of FDA oversight reform—at least in 2022

The ranking member of the Senate Committee on Health, Education, Labor & Pensions (HELP) said there is “no” chance of action on dietary supplement reform in the lame-duck session, reported Axios. But Natural Products Association President Dan Fabricant isn’t popping the champagne yet to celebrate the death of mandatory product listing. Read why.

Botanical sales forecast remains strong

Herbs and Botanicals has been the most persistently growing supplement category since the middle of the past decade. Learn about growth patterns, bestsellers and how quality suppliers, like Inside the Bottle partner PLT Health Solutions, are driving purchasing loyalty with products that deliver. Read the Trend Spotlight: Botanicals.

Hemp 101: Understanding the superfood, new data from SPINS

Hemp has made its way from specialty retailers into mainstream outlets as a common ingredient in the food, beverage, VMS, and body care aisles. Yet, many shoppers are still not sure what hemp is (and what it isn’t). Versatile yet misunderstood, despite challenges hemp continues to provide new sales opportunities across categories. Learn more.

Women in Nutraceuticals seeks to grow female representation

The new nonprofit works to put more women in the C-suite and on the science side of the industry. “This is not a women's organization,” says president, Heather Granato. “It’s not about more women and fewer men. This is about finding parity because it supports the growth of business and it supports the growth of the industry.” Read more.

Dismay over b-NMN debacle reflects growing concerns about FDA

Leaders of the Council for Responsible Nutrition, the American Herbal Products Association and the Consumer Healthcare Products Association expressed concern over the recent FDA determination—and change in position—that the anti-aging ingredient cannot be lawfully marketed in dietary supplements. Read about potential repercussions of drug preclusion.

Why CBD growth has flattened

When CBD first went mainstream in 2019, the market grew by 560%, according to Brightfield Group. But recent earnings results from industry leaders Charlotte’s Web Holdings, Inc. and CV Sciences, Inc. underscore that the CBD gold rush is over. Read about the regulatory, supply chain, consumer and economic trends brands face.

Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.

You May Also Like